213 related articles for article (PubMed ID: 27297582)
1. Lenalidomide, Thalidomide, and Pomalidomide Reactivate the Epstein-Barr Virus Lytic Cycle through Phosphoinositide 3-Kinase Signaling and Ikaros Expression.
Jones RJ; Iempridee T; Wang X; Lee HC; Mertz JE; Kenney SC; Lin HC; Baladandayuthapani V; Dawson CW; Shah JJ; Weber DM; Orlowski RZ
Clin Cancer Res; 2016 Oct; 22(19):4901-4912. PubMed ID: 27297582
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of Epstein-Barr Virus Lytic Reactivation by the Atypical Antipsychotic Drug Clozapine.
Anderson AG; Gaffy CB; Weseli JR; Gorres KL
Viruses; 2019 May; 11(5):. PubMed ID: 31108875
[TBL] [Abstract][Full Text] [Related]
3. Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomas.
Feng WH; Hong G; Delecluse HJ; Kenney SC
J Virol; 2004 Feb; 78(4):1893-902. PubMed ID: 14747554
[TBL] [Abstract][Full Text] [Related]
4. The B-cell specific transcription factor, Oct-2, promotes Epstein-Barr virus latency by inhibiting the viral immediate-early protein, BZLF1.
Robinson AR; Kwek SS; Kenney SC
PLoS Pathog; 2012 Feb; 8(2):e1002516. PubMed ID: 22346751
[TBL] [Abstract][Full Text] [Related]
5. Interferon-γ-inducible protein 16 (IFI16) is required for the maintenance of Epstein-Barr virus latency.
Pisano G; Roy A; Ahmed Ansari M; Kumar B; Chikoti L; Chandran B
Virol J; 2017 Nov; 14(1):221. PubMed ID: 29132393
[TBL] [Abstract][Full Text] [Related]
6. Reactivation of Epstein-Barr Virus from Latency Involves Increased RNA Polymerase Activity at CTCF Binding Sites on the Viral Genome.
Dunn LEM; Lu F; Su C; Lieberman PM; Baines JD
J Virol; 2023 Feb; 97(2):e0189422. PubMed ID: 36744959
[TBL] [Abstract][Full Text] [Related]
7. Viral response to chemotherapy in endemic burkitt lymphoma.
Tang W; Harmon P; Gulley ML; Mwansambo C; Kazembe PN; Martinson F; Wokocha C; Kenney SC; Hoffman I; Sigel C; Maygarden S; Hoffman M; Shores C
Clin Cancer Res; 2010 Apr; 16(7):2055-64. PubMed ID: 20233888
[TBL] [Abstract][Full Text] [Related]
8. Reactivation of Epstein-Barr Virus by HIF-1α Requires p53.
Kraus RJ; Cordes BA; Sathiamoorthi S; Patel P; Yuan X; Iempridee T; Yu X; Lee DL; Lambert PF; Mertz JE
J Virol; 2020 Aug; 94(18):. PubMed ID: 32641480
[TBL] [Abstract][Full Text] [Related]
9. Activation of lytic Epstein-Barr virus (EBV) infection by radiation and sodium butyrate in vitro and in vivo: a potential method for treating EBV-positive malignancies.
Westphal EM; Blackstock W; Feng W; Israel B; Kenney SC
Cancer Res; 2000 Oct; 60(20):5781-8. PubMed ID: 11059774
[TBL] [Abstract][Full Text] [Related]
10. Identification of a new class of small molecules that efficiently reactivate latent Epstein-Barr Virus.
Tikhmyanova N; Schultz DC; Lee T; Salvino JM; Lieberman PM
ACS Chem Biol; 2014 Mar; 9(3):785-95. PubMed ID: 24028149
[TBL] [Abstract][Full Text] [Related]
11. (-)-Epigallocatechin-3-gallate inhibition of Epstein-Barr virus spontaneous lytic infection involves ERK1/2 and PI3-K/Akt signaling in EBV-positive cells.
Liu S; Li H; Chen L; Yang L; Li L; Tao Y; Li W; Li Z; Liu H; Tang M; Bode AM; Dong Z; Cao Y
Carcinogenesis; 2013 Mar; 34(3):627-37. PubMed ID: 23180656
[TBL] [Abstract][Full Text] [Related]
12. The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in
Díaz T; Rodríguez V; Lozano E; Mena MP; Calderón M; Rosiñol L; Martínez A; Tovar N; Pérez-Galán P; Bladé J; Roué G; de Larrea CF
Haematologica; 2017 Oct; 102(10):1776-1784. PubMed ID: 28751557
[TBL] [Abstract][Full Text] [Related]
13. Epstein-Barr virus utilizes Ikaros in regulating its latent-lytic switch in B cells.
Iempridee T; Reusch JA; Riching A; Johannsen EC; Dovat S; Kenney SC; Mertz JE
J Virol; 2014 May; 88(9):4811-27. PubMed ID: 24522918
[TBL] [Abstract][Full Text] [Related]
14. Ceramide promotes lytic reactivation of Epstein-Barr virus in gastric carcinoma.
Kim JY; Min YJ; Lee M-H; An YR; Ashktorab H; Smoot DT; Kwon SW; Lee SK
J Virol; 2024 Feb; 98(2):e0177623. PubMed ID: 38197630
[TBL] [Abstract][Full Text] [Related]
15. Valpromide Inhibits Lytic Cycle Reactivation of Epstein-Barr Virus.
Gorres KL; Daigle D; Mohanram S; McInerney GE; Lyons DE; Miller G
mBio; 2016 Mar; 7(2):e00113. PubMed ID: 26933051
[TBL] [Abstract][Full Text] [Related]
16. A Mechanism-Based Targeted Screen To Identify Epstein-Barr Virus-Directed Antiviral Agents.
Li X; Akinyemi IA; You JK; Rezaei MA; Li C; McIntosh MT; Del Poeta M; Bhaduri-McIntosh S
J Virol; 2020 Oct; 94(21):. PubMed ID: 32796077
[TBL] [Abstract][Full Text] [Related]
17. ΔNp63α promotes Epstein-Barr virus latency in undifferentiated epithelial cells.
Van Sciver N; Ohashi M; Nawandar DM; Pauly NP; Lee D; Makielski KR; Bristol JA; Tsao SW; Lambert PF; Johannsen EC; Kenney SC
PLoS Pathog; 2021 Nov; 17(11):e1010045. PubMed ID: 34748616
[TBL] [Abstract][Full Text] [Related]
18. Histone Loaders CAF1 and HIRA Restrict Epstein-Barr Virus B-Cell Lytic Reactivation.
Zhang Y; Jiang C; Trudeau SJ; Narita Y; Zhao B; Teng M; Guo R; Gewurz BE
mBio; 2020 Oct; 11(5):. PubMed ID: 33109754
[TBL] [Abstract][Full Text] [Related]
19. Pharmacologic Activation of Lytic Epstein-Barr Virus Gene Expression without Virion Production.
Lee J; Kosowicz JG; Hayward SD; Desai P; Stone J; Lee JM; Liu JO; Ambinder RF
J Virol; 2019 Oct; 93(20):. PubMed ID: 31341058
[TBL] [Abstract][Full Text] [Related]
20. Hypoxia-inducible factor-1α plays roles in Epstein-Barr virus's natural life cycle and tumorigenesis by inducing lytic infection through direct binding to the immediate-early BZLF1 gene promoter.
Kraus RJ; Yu X; Cordes BA; Sathiamoorthi S; Iempridee T; Nawandar DM; Ma S; Romero-Masters JC; McChesney KG; Lin Z; Makielski KR; Lee DL; Lambert PF; Johannsen EC; Kenney SC; Mertz JE
PLoS Pathog; 2017 Jun; 13(6):e1006404. PubMed ID: 28617871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
